– Utrecht, The Netherlands - Gilde Healthcare portfolio company RAD-x, the pan-European operator in diagnostic imaging, has announced that it has acquired Teleradiologisches Zentrum Koblenz (TelradKo). TelradKo provides teleradiology services to hospitals and hospital-based imaging…
– Equity Round of $20 million led by Longitude Capital with Silicon Valley Bank Providing a $20 million Credit Facility Irvine, CA – Axonics Modulation Technologies, Inc., a privately-held developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment…
– Utrecht, The Netherlands - AM-Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney…
– Palma, Spain and San Diego, USA - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease…
– With a EUR 190 million market cap, Acacia Pharma realizes the largest new healthcare listing on Euronext in two years. Utrecht, The Netherlands - Acacia Pharma Group plc announces its Initial Global Offering and listing on Euronext Brussels. Shares in the Initial Global Offering…
– Utrecht, The Netherlands - RAD-x, a France-based operator in diagnostic imaging and a portfolio company of Gilde Healthcare, announced that it has acquired Swiss Medical Imaging Investment SA (SMII), which operates the imaging centres Centre d'Imagerie Médicale de la Chaux-de-Fonds,…
– Gilde Healthcare today announces the acquisition of Performation, market leader in business intelligence for healthcare in the Netherlands. The investment will facilitate the expansion of the company's service offering to healthcare clients.
– Utrecht, The Netherlands – Gilde Healthcare announces today that QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated…
– Dublin, Ireland – Foundry Innovation & Research 1, Ltd. ("FIRE1"), today announced the close of a Series C financing totaling EUR 40 Million($48.5 Million). The financing was led by Gilde Healthcare with the participation of Gimv, Seventure, New Enterprise Associates, Lightstone Ventures…
– Cambridge, UK and Indianapolis, US – Acacia Pharma, the specialist pharmaceutical company developing and commercialising hospital products for US and international markets, announces that the New Drug Application (NDA) for BAREMSIS® for the management of post-operative nausea & vomiting…
– The Hague, the Netherlands – NightBalance, a leader in innovative obstructive sleep apnea therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Sleep Position Trainer…
– Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer Palma, Spain and San Diego, USA – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the…
– Irvine, CA – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of bladder and bowel dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics seven new U.S.…
– Top-tier drug development executive joins Board of Directors Important reinforcement for development of lead program in Bronchiolitis Obliterans Munich, Frankfurt, Boston - Breath Therapeutics B.V. (Breath), a company developing advanced drug-aerosol therapeutics in pulmonary…
– LEIDEN, The Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pricing of its previously…
– Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). LCA 10 is one of the most prevalent forms of gene-related blindness…
– Irvine, CA – Axonics Modulation Technologies, Inc., developer of the first rechargeable sacral neuromodulation (r-SNM™) system for the treatment of overactive bladder (OAB) and bowel dysfunction, today announced the U.S. Food & Drug Administration (FDA) has granted an Investigational…
– Leading Care Pathway Management Platform to Dynamically Personalize and Streamline Surgery Experience for Patients BOSTON – Lumeon, the leader in Care Pathway Management, today announced its participation in the Cedars-Sinai Accelerator Powered by Techstars. Through the Accelerator,…
– Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy Divisional patent applications filed to further strengthen Padua intellectual property position LEXINGTON, Mass. and AMSTERDAM, the Netherlands (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy…
– AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates Plans to Initiate Pivotal Study with Enhanced AMT-061 in 2018 Achieves Alignment with FDA on Streamlined Clinical and Regulatory Strategy for AMT-061, Which…
– NightBalance announced the publication of a study comparing its innovative "Sleep Position Trainer" (SPT) to the historic standard of care oral appliance therapy (OAT) in mild to moderate positional obstructive sleep apnea (POSA) over a 12-month period.
– ProQR Therapeutics today announced positive preliminary top-line results from a Phase 1b safety and tolerability clinical trial of QR-010, a novel investigational RNA therapeutic in subjects with cystic fibrosis (CF).
– Sandwich, UK -- Levicept Ltd., an asset-centric biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces that it has commenced its Phase I trial of LEVI-04 in healthy volunteers and osteoarthritis patients…